The third arm of SOLIDARITY combines two HIV protease inhibitor
drugs, lopinavir-ritonavir. The combination shown in vitro and in vivo
potential activity for SARS-CoV and MERS-CoV 38,39 and the mechanism
of action involves the inhibition of Mpro, an essential enzyme
for coronavirus replication 40. Recent report published in The New
England Journal of Medicine41 was not encouraging and the combination
of lopinavir-ritonavir did not differ significantly from “standard care” group.